USPTO serial 78263136
Serial No. 78263136
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 1, 2005
- Examiner
- STIGLITZ, SUSAN R
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with Serial No. 78263136?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
HIGH POINT, NC
HIGH POINT, NC
RH Best, NL
RH Best, NL
RH Best, NL
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Soft gelatin and non-animal film encapsulations and hard core enrobements of various pharmaceutical products, namely, [ AIDS related complex (ARC) therapeutic agents; ] antidiarrheals; antihistamines; analgesics; [ antacids; ] antiflatulents; [ antifungals; ] antiemetics; antipyretics; antiarthritics; [ antiinfectives for the treatment of fungal and viral infections; ] antinauseants; [ antiobesity; blood growth factor products; cancer therapy products; calcium supplements; cardiovascular agents, namely, calcium channel blockers for heart disease; ] cough and cold preparations; [ digestants; diuretics; dermatologicals for the treatment of skin disorders; ] gastrointestinal products, namely, preparations for the treatment of flatulence and constipation; [ hormones; ] histamine H2 receptor antagonists; hypnotics; hypolipidemics; laxatives; musculoskeletal products, namely, [ calcium, ] vitamin D and osteoporosis treatments; psychotherapeutics; ] pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of neurological disorders [ ; drugs for the treatment of respiratory disorders; sedatives; drugs for the treatment of seizure disorders; sleep aids; [ drugs for the treatment of sexual dysfunction; ] transplant and immunosuppressant products, namely, cyclosporine; [ pharmaceutical preparations for the treatment of vascular disorders; ] soft gelatin and non-animal film encapsulations and hard core enrobements of natural medicine products, namely, [ a full line of ] herbal supplements; vitamin and mineral supplements and nutritional supplements, namely, [ a full line of ] vitamin and mineral supplements, nutritional supplements and herbal products; Pharmaceutical preparations, namely, [ AIDS related complex (ARC) therapeutic agents; ] antidiarrheals; antihistamines; analgesics; [ antacids; ] antiflatulents; [ antifungals; ] antiemetics; antipyretics; antiarthritics; [ antiinfectives for the treatment of fungal and viral infections; ] antinauseants; [ antiobesity; blood growth factor products; cancer therapy products; calcium supplements; cardiovascular agents, namely, calcium channel blockers for heart disease; ] cough and cold preparations; [ digestants; diuretics; dermatologicals for the treatment of skin disorders; ] gastrointestinal products, namely, preparations for the treatment of flatulence and constipation; [ hormones; ] histamine H2 receptor antagonists; hypnotics; hypolipidemics; laxatives; musculoskeletal products, namely, [ calcium, ] vitamin D and osteoporosis treatments; psychotherapeutics; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of neurological disorders; drugs for the treatment of respiratory disorders; sedatives; drugs for the treatment of seizure disorders; sleep aids; [ drugs for the treatment of sexual dysfunction; ] transplant and immunosuppressant products, namely, cyclosporine; [ pharmaceutical preparations for the treatment of vascular disorders; ] soft gelatin and non-animal film encapsulations and hard core enrobements of natural medicine products, namely, [ a full line of ] herbal supplements; vitamin and mineral supplements and nutritional supplements, namely, [ a full line of ] vitamin and mineral supplements, nutritional supplements and herbal products ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BANNER LIFE SCIENCES LLC
- Other trademarks owned by BANNER PHARMACAPS INC.
- Other trademarks owned by Banner Pharmacaps B.V.
- Other trademarks owned by Banner Pharmacaps B.V.
- Other trademarks owned by Banner Pharmacaps B.V.
- Other trademarks in Class 005
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 4, 2025 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jul 4, 2025 | RNL2 | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jul 4, 2025 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jul 4, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 28, 2025 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Feb 1, 2024 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Aug 5, 2015 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jan 28, 2015 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jan 28, 2015 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jan 28, 2015 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jan 28, 2015 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 13, 2015 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Dec 31, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 24, 2014 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 30, 2014 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 26, 2012 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jul 25, 2011 | PRA7 | REGISTERED - SEC. 7 REQUEST ABANDONED | — |
| Jul 21, 2011 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 13, 2011 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 6, 2011 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Feb 3, 2011 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Feb 3, 2011 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 21, 2011 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jul 11, 2009 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 11, 2009 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 17, 2006 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 1, 2005 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 9, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 20, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 15, 2004 | CFIT | CASE FILE IN TICRS | — |
| Sep 9, 2004 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 9, 2004 | ALIE | ASSIGNED TO LIE | — |
| Sep 3, 2004 | ALIE | ASSIGNED TO LIE | — |
| Aug 27, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 25, 2004 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 25, 2004 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2004 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Aug 12, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Aug 4, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 4, 2004 | PAPER RECEIVED | — | |
| Jun 25, 2004 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 26, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 26, 2004 | PAPER RECEIVED | — | |
| May 25, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 25, 2003 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2003 | DOCK | ASSIGNED TO EXAMINER | — |